| Particulate methane monooxygenase contains only mononuclear copper centers MO Ross, F MacMillan, J Wang, A Nisthal, TJ Lawton, BD Olafson, ... Science 364 (6440), 566-570, 2019 | 292 | 2019 |
| Protein stability engineering insights revealed by domain-wide comprehensive mutagenesis A Nisthal, CY Wang, ML Ary, SL Mayo Proceedings of the National Academy of Sciences 116 (33), 16367-16377, 2019 | 169 | 2019 |
| Experimental library screening demonstrates the successful application of computational protein design to large structural ensembles BD Allen, A Nisthal, SL Mayo Proceedings of the National Academy of Sciences 107 (46), 19838-19843, 2010 | 80 | 2010 |
| Cell‐free protein synthesis enables high yielding synthesis of an active multicopper oxidase J Li, TJ Lawton, JS Kostecki, A Nisthal, J Fang, SL Mayo, AC Rosenzweig, ... Biotechnology journal 11 (2), 212-218, 2016 | 66 | 2016 |
| A robust heterodimeric Fc platform engineered for efficient development of bispecific antibodies of multiple formats GL Moore, MJ Bernett, R Rashid, EW Pong, DHT Nguyen, J Jacinto, ... Methods 154, 38-50, 2019 | 63 | 2019 |
| Bispecific checkpoint inhibitor antibodies M Bernett, G Moore, J Desjarlais, M Hedvat, C Bonzon, A Nisthal US Patent 10,787,518, 2020 | 61 | 2020 |
| Bispecific checkpoint inhibitor antibodies M Bernett, G Moore, J Desjarlais, M Hedvat, C Bonzon, A Nisthal, ... US Patent 11,492,407, 2022 | 35 | 2022 |
| Bispecific and monospecific antibodies using novel anti-PD-1 sequences M Bernett, G Moore, J Desjarlais, M Hedvat, C Bonzon, A Nisthal, ... US Patent 11,312,770, 2022 | 35 | 2022 |
| Bispecific checkpoint inhibitor antibodies M Bernett, G Moore, J Desjarlais, M Hedvat, C Bonzon, A Nisthal US Patent 11,236,170, 2022 | 35 | 2022 |
| Mechanism of an ATP-independent protein disaggregase: II. distinct molecular interactions drive multiple steps during aggregate disassembly P Jaru-Ampornpan, FC Liang, A Nisthal, TX Nguyen, P Wang, K Shen, ... Journal of Biological Chemistry 288 (19), 13431-13445, 2013 | 35 | 2013 |
| Structural and functional properties of peptides based on the N-terminus of HIV-1 gp41 and the C-terminus of the amyloid-beta protein LM Gordon, A Nisthal, AB Lee, S Eskandari, P Ruchala, CL Jung, ... Biochimica et Biophysica Acta (BBA)-Biomembranes 1778 (10), 2127-2137, 2008 | 19 | 2008 |
| Simultaneous checkpoint-checkpoint or checkpoint-costimulatory receptor targeting with bispecific antibodies promotes enhanced human T cell activation M Hedvat, C Bonzon, MJ Bernett, GL Moore, K Avery, R Rashid, A Nisthal, ... Cancer Research 78 (13_Supplement), 2784-2784, 2018 | 8 | 2018 |
| ASP2138, a novel 2+ 1 format, claudin 18.2 x CD3 bispecific antibody, demonstrates selectivity and activity in preclinical cancer models T Nakazawa, H Tanaka, A Kikuchi, R Rashid, KN Avery, J Qi, A Nisthal, ... Cancer Research 83 (7_Supplement), 2962-2962, 2023 | 5 | 2023 |
| XmAb30819, an XmAb®2+1 ENPP3 x CD3 bispecific antibody for RCC, demonstrates safety and efficacy in in vivo preclinical studies A Nisthal, SH Lee, YK Kim, C Bonzon, R Rashid, KN Avery, L Bogaert, ... Cancer Research 80 (16_Supplement), 2286-2286, 2020 | 5 | 2020 |
| Bispecific claudin-6 x CD3 antibodies in a 2+ 1 format demonstrate selectivity and activity on human ovarian cancer cells MS Faber, SH Lee, YK Kim, J Qi, KN Avery, DHT Nguyen, R Rashid, ... Cancer Res 81 (Suppl 13), S1860, 2021 | 4 | 2021 |
| Untargeted and targeted IL-10 Fc-fusion proteins G Moore, R Varma, YK Kim, R Rashid, A Nisthal, J Diaz, M Bernett, ... US Patent 12,006,345, 2024 | 3 | 2024 |
| Heterodimeric antibodies that bind fibroblast activation protein J Desjarlais, A Nisthal, S Chu US Patent 10,982,006, 2021 | 3 | 2021 |
| Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3 JR Desjarlais, A Nisthal, M Hedvat, MA Dragovich US Patent 11,919,956, 2024 | 2 | 2024 |
| Heterodimeric antibodies that bind CD3 and CLDN6 MS Faber, SH Lee, YK Kim, J Qi, KN Avery, SY Chu, A Nisthal, MJ Bernett, ... US Patent 11,739,144, 2023 | 2 | 2023 |
| 1372 XmAb143, an engineered IL18 heterodimeric Fc-fusion, features improved stability, reduced potency, and insensitivity to IL18BP A Nisthal, SH Lee, C Bonzon, R Love, K Avery, R Rashid, ... J. ImmunoTherapy Cancer 10, A1426, 2022 | 2 | 2022 |
